Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Devonian Health Group, Inc. ( (TSE:GSD) ) has issued an update.
Devonian Health Group Inc. has filed a new provisional patent application for the use of Thykamine™ in treating metabolic dysfunction-associated steatotic liver disease (MASLD), including MASH. This move is part of the company’s strategy to expand its patent portfolio and demonstrates the potential broad application of their technology, potentially impacting the treatment landscape for MASLD, a prevalent chronic liver disease.
More about Devonian Health Group, Inc.
Devonian Health Group Inc. is a clinical-stage corporation focused on developing unique solutions to inflammatory diseases.
YTD Price Performance: -18.75%
Average Trading Volume: 25,433
Technical Sentiment Consensus Rating: Buy
Current Market Cap: C$19.27M
For detailed information about GSD stock, go to TipRanks’ Stock Analysis page.
